Reticulocalbin 3 in cirrhosis: liver biomarker or marker of systemic decompensation? [0.03%]
网状素3在肝硬化中的作用：肝脏生物标志物还是全身失代偿的标志？
Chetan R Kalal,Piyush Gupta
Chetan R Kalal
Safety and Effectiveness of GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Liver Transplant Recipients with Diabetes [0.03%]
糖尿病肝移植受者的GLP-1受体激动剂和SGLT-2抑制剂的安全性和有效性
Alessandra Mazzola,Philippe Sultanik,Aida Rebiha et al.
Alessandra Mazzola et al.
Background: We studied the safety and effectiveness of glucagon-like peptide-1 receptor agonists (GLP1-RAs) and sodium-glucose co-transporter-2 inhibitors (SGLT2is) in liver transplant recipients with diabetes. ...
Efficacy and Safety of Empagliflozin in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis [0.03%]
恩格列净治疗代谢紊乱相关肝脂肪变的疗效和安全性：系统评价和 meta 分析
Shambo Samrat Samajdar,Shashank R Joshi,Gaurab Bhaduri et al.
Shambo Samrat Samajdar et al.
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is now the leading cause of chronic liver disease and is tightly linked to obesity, insulin resistance and type 2 diabetes. There are limited dr...
Comment on "Predictors of in-hospital mortality among patients with cirrhosis and renal replacement therapy in the ICU: a retrospective cohort study" [0.03%]
关于“ICU中肝病伴肾脏替代治疗患者院内死亡预测因素：一项回顾性队列研究”的评论
Yalong Chen,Yan Su,Yanlong Li
Yalong Chen
Re: "Alcohol-related cognitive impairment confounds covert hepatic encephalopathy screening by PHES and the Simplified Animal Naming Test" - Brunet et al., Clinics and Research in Hepatology and Gastroenterology, 2026 [0.03%]
关于“酒精相关性认知障碍干扰了PHES和简化动物命名测试对隐匿性肝性脑病的筛查”——Brunet等，临床与研究在肝脏病学和胃肠病学，2026年
Lyès Kheloufi,Clara Modolo,Philippe Sultanik et al.
Lyès Kheloufi et al.
Valentina Zen,Francesca Bof,Rossana Intini et al.
Valentina Zen et al.
Anal squamous cell carcinoma (SCAC) is a relatively rare malignancy, but its incidence has been rising, largely due to infection with human papillomavirus (HPV), which is the main etiological driver. HPV vaccination and treatment of high-gr...
Clinical Applications of Anti-centromere Antibody in Primary Biliary Cholangitis [0.03%]
抗着丝点抗体在原发性胆汁性肝硬化临床应用中的意义
Song He,Li-Ping Ke,Zhi-Zhen Li
Song He
Rapidly progressive cirrhosis and portal hypertension in a Tunisian child with PFIC5 due to a novel homozygous NR1H4 frameshift mutation [0.03%]
突变引起的进行性家族性肝内胆汁淤积症5型导致的快速进展性门脉高压和肝硬化病例报告
Manel Hsairi,Manel Feki,Manel Guirat et al.
Manel Hsairi et al.
Portal inflammation, cholangiolitis and ductular reaction as histological clues to malnutrition-induced hepatic decompensation [0.03%]
门脉炎症、胆管炎和导管反应作为营养不良引起的肝衰竭的组织学线索
Nicolas Lanthier,Bénédicte Delire,Géraldine Dahlqvist et al.
Nicolas Lanthier et al.